Gepotidacin  Study BTZ116577 [EAGLE 1]

Phase 3 Background Information

– Gepotidacin, a novel antibacterial agent in P3 development by GSK, in partnership with BARDA (Agreement HHSO100201300011C), for GC and uUTI.

– A Study Evaluating Efficacy and Safety of Gepotidacin Compared With Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea - Full Text View - ClinicalTrials.gov. NCT04010539

– Study start October 2019

– Original study completion April 2021 (estimated 600 participants enrolled in 18 months), revised estimated completion date September 8th, 2023.

– Individuals aged 12 years and older are eligible, body weight of >45 kilogram (kg)

– Study follows FDA guidance for Industry

– Study has sites open in 6 countries (US, AUS, UK, GER, Spain, Mexico) with the last country opening sites beginning April 21

– COVID-19 pandemic driven operational challenges
Operational Challenge—Selection of Comparator:

Current Standard of Care (SoC) by Country

- Phase 3 protocol BTZ116577 comparator 500mg IM ceftriaxone (CRO) plus 1gm oral azithromycin (AZM)

<table>
<thead>
<tr>
<th>Country</th>
<th>Recommended SoC for urogenital NG</th>
</tr>
</thead>
<tbody>
<tr>
<td>USA</td>
<td>500mg CRO: Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020</td>
</tr>
<tr>
<td></td>
<td>Previous: 250mg CRO plus 1g AZM: <a href="https://www.cdc.gov/std/tg2015/gonorrhea.htm">https://www.cdc.gov/std/tg2015/gonorrhea.htm</a></td>
</tr>
<tr>
<td>Australia</td>
<td>500mg CRO plus 1g AZM: <a href="http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management">http://www.sti.guidelines.org.au/sexually-transmissible-infections/gonorrhoea#management</a></td>
</tr>
<tr>
<td>UK</td>
<td>1g CRO: <a href="https://www.bashhguidelines.org/current-guidelines/all-guidelines/">https://www.bashhguidelines.org/current-guidelines/all-guidelines/</a></td>
</tr>
<tr>
<td>Spain</td>
<td>500mg CRO plus 1g AZM:</td>
</tr>
<tr>
<td>Germany</td>
<td>1g CRO plus 1.5g AZM: BMC Infect Dis. 2018; 18: 44.</td>
</tr>
<tr>
<td>Mexico</td>
<td>250mg CRO plus 1g AZM: WHO 2016 guidelines: <a href="https://www.who.int/selection_medicines/committees/expert/21/applications/s6_gonorrhoea.pdf">https://www.who.int/selection_medicines/committees/expert/21/applications/s6_gonorrhoea.pdf</a></td>
</tr>
</tbody>
</table>

- With the exception of US and UK, all other countries use dual therapy with AZM at varying doses.
- Global agreement on SoC or comparator for Clinical trial purposes urgently needed
Operational Challenge

Culture vs NAAT testing as primary endpoint

- Primary endpoint is culture confirmed eradication of infection and defines the primary microITT population
- NAAT testing used to enrich for enrollment of evaluable participants & secondary endpoint

HOWEVER

- Principal Investigator Capability and Capacity to participate in clinical trials is a challenge:
  - Very little training in obtaining cultures & bedside plating or local lab availability to maintain viability
  - Limited global network of experts & competition from sponsors

- For all sponsors, access to the local/regional WHO/GISP testing laboratories who have reliable culture and isolate transport conditions established would reduce variability and out of window shipments and help improve pathogen recovery and isolate transport

- Consideration for NAAT as primary endpoint and culture as a secondary endpoint
  - More countries and PIs utilize NAAT
  - Culture and susceptibility testing still required to determine Breakpoints from a subset of sites

FDA/CDC/NIAID Workshop 23rd April 2021
Operational Challenge

Body site sampling/ Enriching participant populations/ Multidose regimen

– Sampling at all three-body sites- urogenital, pharyngeal & rectal for both culture and NAAT is a huge burden for both the participant and the site staff
  – Including testing for CT, M.gen
– Enriching for female and adolescent participants is very challenging:
  – 50% of women are asymptomatic, difficult to obtain cultures and present at OB/GYN clinics
  – Incidence of STIs highest in adolescents – difficult to recruit and obtain consent
– Multidose regimen requires operational considerations to ensure second dose is taken
  – Gepotidacin is a two-dose regimen
Pandemic Related Operational Challenges

COVID-19 has had a significant impact on the trial from both a startup and enrollment

- Sexual Health deprioritized by:
  - Regulators, Ethics/IRBs (delays to review & CTA approvals)
  - Academic Institutions (Re deployment of Infectious Disease Specialists to focus on COVID)
  - Health Authorities (non-essential clinical trials put on hold in UK & AUS, re application required)

- Study Visits
  - Pandemic restrictions and lockdowns impact clinic visits, with time on site becoming a huge burden
  - Participants are reluctant to spent time in clinic

- Can Visits be Remote
  - E- consent – not acceptable in all countries
  - Telemedicine to collect Med and Sexual Hx and remote F/U visit
Non-inferiority (NI) Margin

NI margin and study N vs highly effective gold standard comparator

- Uncomplicated Gonorrhea FDA guidance released in August 2015 proposed a NI margin of 10%.
- This NI margin was based on trials in which effective therapy was compared to ineffective or less effective therapy (3 trials identified, 2 from 1986 and 1 from 2001)
- More recent trials allow a NI margin to be recalculated using SOC (ceftriaxone) and proxy for placebo.
- Given the obstacles to developing a new drug in GC, a larger clinically acceptable difference (NI margin) could be considered based on an updated meta-analysis of more recent studies
Pragmatic Trial Considerations

New drugs for GC therapy are urgently needed.

- All current sponsors are utilizing public, private partnerships
  - Can public funding be utilized more effectively
  - Platform Trial design or a master protocol could drive efficiency
    - For example: sponsored by NIAID, a single comparator arm with multiple sponsors joining the trial
  - A global network of GC professionals supporting the platform study
  - Sites specializing in recruiting women
  - Sites with ethical pre-approved to recruit adolescents
- Harmonized regulatory CTA approval and Ethics review
- NAAT testing for primary population definition and primary endpoint
- Shared access to local/regional WHO/GISP testing laboratories for all cultures